The evolving role of aminolevulinic acid hydrochloride with photodynamic therapy in photoaging.
The safety and efficacy of treating individuals who presented with multiple actinic keratosis (AK) lesions with 5-aminolevulinic acid (ALA) in combination with photodynamic therapy (PDT) were documented in a phase III trial. This report highlights results of this phase III trial and reviews 2 specific case studies treated with ALA/PDT who presented with both multiple nonhyperkeratotic AK lesions and moderate-to-severe photodamage. Treatment consisted of a 2-step process performed by the investigator. In addition to the pretreatment evaluation, each subject was evaluated at 1- and 2-month intervals after each treatment of ALA/PDT. Clinical findings reveal complete healing at the site of ALA/PDT without scarring or changes in pigmentation, as well as significant changes in signs of photodamage, such as improvement in skin elasticity and reduction in skin thickening.
Gold
Michael H
MH
Gold Skin Care Center, Nashville, Tennessee, USA.
D000279:Administration, Cutaneous; D000368:Aged; D000369:Aged, 80 and over; D000622:Aminolevulinic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D005148:Facial Dermatoses / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007642:Keratosis / Q000188:drug therapy* / Q000473:pathology; D008137:Longitudinal Studies; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012536:Scalp Dermatoses / Q000188:drug therapy* / Q000473:pathology; D015595:Skin Aging / Q000187:drug effects* / Q000473:pathology; D016896:Treatment Outcome
D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid